A phase I dose-finding study of vorinostat (V) combined with capecitabine (X) and cisplatin (P) as first-line therapy in patients with advanced gastric cancer.
Changhoon Yoo
No relevant relationships to disclose
Min-Hee Ryu
No relevant relationships to disclose
Baek-Yeol Ryoo
No relevant relationships to disclose
Dong Hoe Koo
No relevant relationships to disclose
Inkeun Park
No relevant relationships to disclose
Yoon-Koo Kang
Research Funding - Merck